6odl: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
<table><tr><td colspan='2'>[[6odl]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ODL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ODL FirstGlance]. <br> | <table><tr><td colspan='2'>[[6odl]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ODL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ODL FirstGlance]. <br> | ||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=M7V:( | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=M7V:(1~{S},2~{R})-2-[(1~{S})-1-azanyl-2-oxidanyl-2-oxidanylidene-ethyl]-1-butyl-cyclopropane-1-carboxylic+acid'>M7V</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6odl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6odl OCA], [https://pdbe.org/6odl PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6odl RCSB], [https://www.ebi.ac.uk/pdbsum/6odl PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6odl ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6odl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6odl OCA], [https://pdbe.org/6odl PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6odl RCSB], [https://www.ebi.ac.uk/pdbsum/6odl PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6odl ProSAT]</span></td></tr> | ||
</table> | </table> | ||
Latest revision as of 14:14, 30 October 2024
Crystal structure of GluN2A agonist binding domain with 4-butyl-(S)-CCG-IVCrystal structure of GluN2A agonist binding domain with 4-butyl-(S)-CCG-IV
Structural highlights
FunctionNMDE1_RAT NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits. Publication Abstract from PubMedWe developed a versatile stereoselective route for the synthesis of new 2'-(S)-CCG-IV analogues. The route allows for late stage diversification and thereby provides access to a great variety of conformationally restricted cyclopropyl glutamate analogues. A selection of the 2'-(S)-CCG-IV analogues were evaluated using two-electrode voltage-clamp electrophysiology at recombinant GluN1/GluN2A-D receptors, demonstrating that agonists can be developed with GluN2 subunit-dependent potency and agonist efficacy. We also describe a crystal structure of the GluN2A agonist binding domain in complex with 2'-butyl-(S)-CCG-IV that determines the position of 2'-substituents in (S)-CCG-IV agonists in the glutamate binding site and provides further insight to the structural determinants of their agonist efficacy. The stereoselective synthesis described here enables versatile and straight-forward modifications to diverse analogues of interest for the development of potent subtype-specific NMDA receptor agonists and other applications. Stereoselective synthesis of novel 2'-(S)-CCG-IV analogues as potent NMDA receptor agonists.,Maolanon A, Papangelis A, Kawiecki D, Mou TC, Syrenne JT, Yi F, Hansen KB, Clausen RP Eur J Med Chem. 2021 Feb 15;212:113099. doi: 10.1016/j.ejmech.2020.113099. Epub , 2020 Dec 18. PMID:33383257[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||